Concerns were raised about the use of RAAS inhibitors (RAASi), such as ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs), in COVID-19 patients, due to the potential upregulation of ACE2. The gene discussed is ACE2; the disease is COVID-19.